ERBB2 and neoplasm: The CT26 hHER2 was established by engineering CT-26 cells to express human HER237 and this tumor model was used to compare the therapeutic efficacy of HER2-DC1 i.t. combined with anti-human HER2 antibodies trastuzumab and pertuzumab or T-DM1 versus chemotherapy paclitaxel combined with trastuzumab and pertuzumab.